Richard Maury Stone

Prognostic and Therapeutic Implications of BRAF Mutations in Acute Myeloid Leukemia

This study identifies BRAF mutations in AML, showing poor outcomes and unique co-mutation patterns, suggesting potential targeted therapies.

Genotype-immunophenotype relationships in NPM1-mutant AML clonal evolution uncovered by single cell multiomic analysis

This study uses single-cell multiomic analysis to reveal genotype-immunophenotype relationships and clonal evolution in NPM1-mutant AML across disease stages.

PTPN11 Mutation Clonal Hierarchy in Acute Myeloid Leukemia

This study identifies PTPN11 mutations as potential initiating events in AML when paired with NPM1 mutations, revealing their co-driver role and immune diversity in patient samples.

Dynamic BH3 profiling predicts clinical outcomes in acute myeloid leukemia

This paper uses Dynamic BH3 Profiling to predict clinical outcomes in AML by assessing drug-induced apoptotic priming in patient samples.

Sialylated CD43 is a glyco-immune checkpoint for macrophage phagocytosis

The paper identifies CD43 as a glyco-immune checkpoint that inhibits human macrophage phagocytosis, showing that O-linked glycosylation and sialylation pathways regulate this process in AML.

Translation Initiation Represents an Acute Myeloid Leukemia Cell Vulnerability That Can Be Co-Targeted With BCL-2 Inhibition

The paper identifies EIF4A1 as a vulnerability in AML cells and shows that combining Zotatifin with Venetoclax enhances apoptosis and survival in AML models.